Intensity Therapeutics, Inc. (INTS) stock
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.28+0.19 (+6.15%)
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Intensity Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Intensity Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$9.07M. For fiscal 2025 it was -$9.23M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.23M | – |
| FY2024 | Dec 31, 2024 | -$15.22M | – |
| FY2023 | Dec 31, 2023 | -$7.21M | – |
| FY2022 | Dec 31, 2022 | -$5.48M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.50M | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.34M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.99M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.67M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.21M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.37M | – |
| Q4 FY2023 | Dec 31, 2023 | -$946.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$239.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$901.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.63M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.03M | – |
See a number that looks wrong?